NeoStem Inc.

Related Content

NeoStem, PreSERVE study, AMI, ACC.15, NBS10, CD34 stem cells
Feature | Heart Failure
NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results

July 17, 2015 - NeoStem Inc. presented updated efficacy and safety results from the one-year follow-up for its Phase 2 ...

Home July 17, 2015
arrow
News
Stem Cell Company Amorcyte Announces Expansion of Intellectual Property

January 13, 2012 — Amorcyte Inc.,a NeoStem Inc. company, announced the expansion of intellectual property protection ...

Home January 13, 2012
arrow
News
NeoStem, Amorcyte to Initiate Phase 2 Stem Cell Product Trial

October 24, 2011 — NeoStem Inc. and Amorcyte Inc announced the closing of their previously publicized merger transaction ...

Home October 24, 2011
arrow
News
NeoStem Provides Update on Amorcyte Stem Cell Treatment Clinical Progress

August 19, 2011 — NeoStem Inc., an international biopharmaceutical company, reported progress toward commencement of a ...

Home August 19, 2011
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now